Complete Response Letter for IPX 203 for treatment of Parkinson's

Amneal Pharmaceuticals Inc announced topline data from the Phase 3 RISE-PD trial evaluating IPX-203 in patients with

Join us as we present data evaluating our investigational drug IPX-203 in Parkinson' s disease patients with motor fluctuations at the 4th

ipx969 IPX203 is a novel oral formulation of carbidopalevodopa , which is a well-established drug combination used for the management of

ipx964 Amneal Pharmaceuticals announced positive results yesterday from a pivotal Phase III clinical trial that evaluated IPX-203 in patients with